Fiscal Year Ending May 2027 Q1 Financial Summary [Japanese GAAP] (Consolidated)

Summary of Results

In Q1 of the current fiscal year, revenue was 5,899,896 thousand yen, up 18.0% year-over-year, and EBITDA was 236,299 thousand yen, up 89.7%, contributing to significant revenue and profit growth. Operating income was 83,953 thousand yen and ordinary income was 68,885 thousand yen, returning to profitability. Net loss attributable to owners of parent for the quarter improved slightly to 10,223 thousand yen. By segment, Medical Care Sales recorded higher revenue and profit, Healthcare Sales saw EBITDA deterioration due to advertising investments, and Healthcare Marketing achieved notable EBITDA growth. Supplementary materials to the financial summary are available.

Outlook and Financial Position

The full-year forecasts for the fiscal year ending May 2027 are: revenue 26,500 hundred million yen, EBITDA 1,700 hundred million yen, operating income 1,050 hundred million yen, ordinary income 1,000 hundred million yen, and net income attributable to owners of parent 550 hundred million yen. These forecasts assume the impact of business combinations including provisional accounting for the quarterly results, and actual performance may vary due to future factors. Financial position: total assets 9,594,879 thousand yen, net assets 1,498,466 thousand yen, and equity ratio 12.5% (previous period 12.7%).